Document Detail

Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells.
MedLine Citation:
PMID:  9419346     Owner:  NLM     Status:  MEDLINE    
Multiple myeloma (MM) is a B cell malignancy characterized by the expansion of monoclonal Ig-secreting plasma cells with low proliferative activity. It is postulated that inhibition of physiologic cell death is an underlying factor in the pathophysiology of MM. The development of chemoresistance is a common feature in patients with MM. In the present studies, hexamethylene bisacetamide (HMBA), a hybrid polar compound that is a potent inducer of terminal differentiation of various transformed cells, is shown to inhibit the growth of several human myeloma cell lines (ARP-1, U266, and RPMI 8226), including doxorubicin-resistant RPMI 8226 variants that overexpress the multidrug-resistance gene, MDR-1, and its product, p-glycoprotein. In addition to growth arrest and suppression of clonogenicity, HMBA induces apoptosis both in freshly isolated human myeloma cells and in cell lines, as determined by morphologic alterations, cell cycle distribution and endonucleosomal DNA fragmentation. Further, HMBA decreases BCL-2 protein expression in myeloma cells within 12-48 hr. Overexpression of BCL-2 protein in ARP-1 cells confers resistance to HMBA-induced apoptosis. Taken together, these data suggest that HMBA is a potent inducer of apoptosis in human myeloma cells, which may act through suppressing the anti-apoptotic function of the bcl-2 gene. HMBA, and related hybrid polar compounds, may prove useful in the management of this presently incurable disease.
D S Siegel; X Zhang; R Feinman; T Teitz; A Zelenetz; V M Richon; R A Rifkind; P A Marks; J Michaeli
Related Documents :
16079106 - T-bet-positive and irta1-positive monocytoid b cells differ from marginal zone b cells ...
18767026 - Non-peptidic small molecule inhibitors against bcl-2 for cancer therapy.
21098876 - Effect of erythropoietin, 5-fluorouracil and sn-38 on the growth of dld-1 cells.
8698136 - Monocytic differentiation and synthesis of proteins associated with apoptosis in human ...
15708496 - Localization of m2 muscarinic receptor protein in parvalbumin and calretinin containing...
17586456 - Development of a cell-based fluorescence resonance energy transfer reporter for bacillu...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Proceedings of the National Academy of Sciences of the United States of America     Volume:  95     ISSN:  0027-8424     ISO Abbreviation:  Proc. Natl. Acad. Sci. U.S.A.     Publication Date:  1998 Jan 
Date Detail:
Created Date:  1998-02-18     Completed Date:  1998-02-18     Revised Date:  2013-04-16    
Medline Journal Info:
Nlm Unique ID:  7505876     Medline TA:  Proc Natl Acad Sci U S A     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  162-6     Citation Subset:  IM    
Program of Cell Biology, The University of Arkansas, Little Rock, AR 72205, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetamides / pharmacology*
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects*
Down-Regulation* / drug effects
Immunoenzyme Techniques
Multiple Myeloma / metabolism*
Proto-Oncogene Proteins c-bcl-2 / genetics,  metabolism*
Tumor Cells, Cultured
Reg. No./Substance:
0/Acetamides; 0/Antineoplastic Agents; 0/Proto-Oncogene Proteins c-bcl-2; 3073-59-4/hexamethylene bisacetamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation a...
Next Document:  Creation of monosomic derivatives of human cultured cell lines.